KETINK 100 MG/ML SOLUTION FOR INJECTION FOR CATTLE, HORSES AND PIGS

Country: Irlanda

Lingwa: Ingliż

Sors: HPRA (Health Products Regulatory Authority)

Ixtrih issa

Ingredjent attiv:

KETOPROFEN

Disponibbli minn:

Industrial Veterinaria, S.A.

Kodiċi ATC:

QM01AE03

INN (Isem Internazzjonali):

KETOPROFEN

Dożaġġ:

100 Mg/Ml

Għamla farmaċewtika:

Solution for Injection

Tip ta 'preskrizzjoni:

POM

Grupp terapewtiku:

Bovine, Equine - Food, Porcine

Żona terapewtika:

Ketoprofen

Indikazzjonijiet terapewtiċi:

N.S.A.I.D

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2012-02-10

Karatteristiċi tal-prodott

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Ketink 100 mg/ml solution for injection for cattle, horses and pigs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains:
ACTIVE SUBSTANCE:
Ketoprofen 100 mg
EXCIPIENTS:
Benzyl alcohol (E1519) 10 mg
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
A clear, colourless to yellow solution. Free from visible particles.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle, pigs and horses.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
_Cattle:_ Anti-inflammatory and analgesic treatment of diseases in the
musculoskeletal system and the udder.
_Pigs:_
Anti-inflammatory and antipyretic treatment
of
Postpartum Dysgalactia Syndrome -PDS-
(Metritis Mastitis
Agalactia Syndrome) and respiratory diseases.
_Horses:_ Anti-inflammatory and analgesic treatment of diseases in the
musculoskeletal system and joints.
Symptomatic analgesic treatment for colic. Postoperative pain and
swelling.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substance, or to
any of the excipients.
Do not
use in animals suffering from gastro-intestinal
lesions,
haemorrhagic diathesis,
blood dyscrasia,
impaired
hepatic, cardiac or renal function.
Do not use in foals in their first month of life.
Do not use other non-steroidal anti-inflammatory drugs (NSAIDs)
concurrently or within 24 hours of each other.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_

                                
                                Aqra d-dokument sħiħ
                                
                            

Fittex twissijiet relatati ma 'dan il-prodott